NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 160 filers reported holding NEVRO CORP in Q1 2023. The put-call ratio across all filers is 0.53 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,049 | -23.3% | 158,642 | +1.5% | 0.00% | -20.0% |
| Q2 2023 | $3,975 | -22.6% | 156,373 | +10.1% | 0.01% | -28.6% |
| Q1 2023 | $5,134 | -7.9% | 142,038 | +0.9% | 0.01% | -12.5% |
| Q4 2022 | $5,575 | -99.9% | 140,792 | -21.7% | 0.01% | -33.3% |
| Q3 2022 | $8,383,000 | -14.7% | 179,914 | -19.8% | 0.01% | -7.7% |
| Q2 2022 | $9,831,000 | -7.2% | 224,317 | +53.2% | 0.01% | +8.3% |
| Q1 2022 | $10,589,000 | +30154.3% | 146,403 | +33633.4% | 0.01% | – |
| Q4 2021 | $35,000 | -18.6% | 434 | +15.7% | 0.00% | – |
| Q3 2021 | $43,000 | -95.8% | 375 | -94.9% | 0.00% | -100.0% |
| Q1 2021 | $1,017,000 | -35.1% | 7,297 | -19.5% | 0.00% | -50.0% |
| Q4 2020 | $1,568,000 | -60.6% | 9,059 | -87.8% | 0.00% | -75.0% |
| Q2 2015 | $3,984,000 | -35.8% | 74,125 | -42.7% | 0.01% | -38.5% |
| Q1 2015 | $6,203,000 | – | 129,425 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |